[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"endoscopic-submucosal-dissection\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:endoscopic-submucosal-dissection":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,10,0,[8,41,71,93,116,142,167,198,220,247],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":22,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":27,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100288789","endoscopic-submucosal-dissection-for-early-gi-neoplasia-in-the-united-kingdom-100288789",false,"NCT03039309","Endoscopic Submucosal Dissection for Early GI Neoplasia in the United Kingdom","Endoscopic Submucosal Dissection in the Treatment of Early Gastrointestinal Neoplasia: A UK Cohort Study to Assess Effectiveness and Safety","ESDUK","Inclusion Criteria:\n\n* Male or Female, aged 18 years or above undergoing endoscopic submucosal dissection\n* Participant is able to give informed consent for participation in the study\n\nExclusion Criteria:\n\n* Patients under the age of 18\n* Patients unable to give informed consent","ALL","18 Years",{"count":20,"type":21},500,"ESTIMATED","2 Years","OBSERVATIONAL","Multicentre cohort study on the use of endoscopic submucosal dissection for the treatment of early gastrointestinal neoplasia.",[26],"Endoscopic Submucosal Dissection",[26],"RECRUITING","2026-06-24",{"date":31,"type":32},"2026-06-29","ACTUAL",{"date":34,"type":32},"2016-08-05",{"date":36,"type":21},"2028-08-04",{"name":38,"class":39},"Portsmouth Hospitals NHS Trust","OTHER_GOV",1,{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":4,"eligibilityCriteria":47,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":48,"targetDuration":4,"studyType":50,"phases":51,"briefSummary":53,"conditions":54,"keywords":56,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":61,"startDateStruct":63,"completionDateStruct":65,"leadSponsor":67,"locationsCount":70},"100577963","early-feeding-versus-delayed-feeding-after-colorectal-endoscopic-submucosal-dissection-100577963","NCT06805123","Early Feeding Versus Delayed Feeding After Colorectal Endoscopic Submucosal Dissection","Comparison of Clinical Outcomes According to Timing of Dietary Restart After Colorectal Endoscopic Submucosal Dissection: A Prospective, Multicenter, Randomized Controlled Trial","Inclusion Criteria: Patients undergoing colorectal endoscopic submucosal dissection for the following lesions:\n\n* Differentiated early colorectal cancer confined to the mucosa, without ulcers, and measuring ≤5 cm\n* Laterally spreading tumors measuring ≥2 cm\n* Sessile polyps measuring ≥2 cm\n* Adenomas accompanied by fibrosis\n* Differentiated early cancer of the colon or rectum without lymph node metastasis, aside from those covered by partial self-payment insurance (Korean National Health insurance)\n* Submucosal tumors of the colon or rectum\n* Patients who have signed the consent form to participate in this study\n\nExclusion Criteria:\n\n* Under 18 years of age\n* Patients with unresolved colorectal cancer\n* Patients with non-remissive inflammatory bowel disease (IBD)\n* Patients with blood coagulation disorders\n* Patients with a prothrombin time (PT) INR ≥ 1.5 despite medical correction\n* Pregnant patients\n* Patients who refuse to participate in this study",{"count":49,"type":21},204,"INTERVENTIONAL",[52],"NA","Currently, there are no clear guidelines regarding the optimal timing for dietary restart after gastrointestinal endoscopic submucosal dissection (ESD). While several studies have addressed upper gastrointestinal ESD, a meta-analysis reported that early feeding, initiated within one day after the procedure, showed no statistically significant difference in complication rates compared to delayed feeding initiated after two or more days. Moreover, early feeding was associated with shorter hospital stays and higher patient satisfaction. However, to the best of our knowledge, no studies have investigated early feeding in colorectal ESD.\n\nOn the other hand, in the context of surgical procedures involving the gastrointestinal tract, several studies suggest that early feeding may offer clinical advantages over delayed feeding.\n\nThe aim of this study is to explore the optimal timing for dietary restart following colorectal ESD. In the early feeding group (\\\u003C24 hours), patients begin water intake if no abnormalities are observed during a follow-up examination conducted two hours post-procedure. If no further issues arise after an additional two hours, a liquid diet is initiated. In contrast, the delayed feeding group (\\>24 hours) maintains fasting on the day of the procedure and begins a liquid diet the following day. The study will compare the early and delayed feeding groups in terms of early post-procedural adverse events (occurring within 24 hours after the procedure)(e.g., bleeding, perforation, post-coagulation syndrome), patient satisfaction, and delayed post-procedural adverse events (occurring more than 24 hours after the procedure).",[26,55],"Colorectal Neoplasms",[57,58,59],"colorectum","endoscopic submucosal dissection","feeding","2026-06-14",{"date":62,"type":32},"2026-06-17",{"date":64,"type":32},"2025-02-01",{"date":66,"type":21},"2026-12-30",{"name":68,"class":69},"Pusan National University Hospital","OTHER",5,{"id":72,"slug":73,"hasResults":11,"nctId":74,"briefTitle":75,"officialTitle":76,"acronym":4,"eligibilityCriteria":77,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":78,"enrollmentInfo":79,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":81,"conditions":82,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":83,"lastUpdatePostDateStruct":84,"startDateStruct":86,"completionDateStruct":88,"leadSponsor":90,"locationsCount":92},"100284991","multi-center-evaluation-of-the-clinical-utility-of-esd-in-the-western-population-100284991","NCT02989818","Multi-center Evaluation of the Clinical Utility of ESD in the Western Population","Multi-center Prospective Evaluation of the Clinical Utility of Endoscopic Submucosal Dissection (ESD) in the Western Population","Inclusion Criteria:\n\n* a. Age 18 years or older.\n* b. Scheduled to undergo ESD as part of their standard of care.\n\nExclusion Criteria:\n\n* a. Any contraindication to performing endoscopy.\n* b. Participation in another research protocol that could interfere or influence the outcome measures of the present study.\n* c. Patient is unable\u002Funwilling to provide informed consent.","100 Years",{"count":80,"type":21},300,"The aim of this multi-center study is to prospectively document the clinical utility of ESD.",[26],"2026-04-06",{"date":85,"type":32},"2026-04-07",{"date":87,"type":32},"2016-03",{"date":89,"type":21},"2028-01",{"name":91,"class":69},"University of Florida",3,{"id":94,"slug":95,"hasResults":11,"nctId":96,"briefTitle":97,"officialTitle":98,"acronym":4,"eligibilityCriteria":99,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":100,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":102,"conditions":103,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":107,"lastUpdatePostDateStruct":108,"startDateStruct":110,"completionDateStruct":112,"leadSponsor":114,"locationsCount":40},"100552714","novel-bipolar-radiofrequency-ablation-knife-in-esophageal-lesions-100552714","NCT06476678","Novel Bipolar Radiofrequency Ablation Knife in Esophageal Lesions","Prospective Multicenter Trial Evaluating the Efficacy and Feasibility of a Novel Bipolar Radiofrequency Ablation Knife in Esophageal Endoscopic Submucosal Dissection","Inclusion Criteria:\n\n* Patient is \\>18 years of age\n* Patient can provide informed consent\n* Patient is referred for resection of precancerous lesions meeting the following criteria:\n\n  * Mucosal based polyp\n  * Located gastroesophageal junction (GEJ) or proximal to GEJ\n  * No previous endoscopic resection attempted (EMR or ESD)\n\nExclusion Criteria:\n\n* Patients with International Normalized Ratio (INR) \\>1.5 or Platelets \\\u003C50,000\n* Lesions extending past GEJ\n* Subepithelial lesions",{"count":101,"type":21},50,"Both Baylor St Luke's Medical Center and Mayo Scottsdale are considered endoscopic submucosal dissection (ESD) centers of excellence. The investigators at Baylor College of Medicine have previously reported our Esophageal ESD experience using the monopolar current knife. Moreover, the research team have previously reported on the clinical efficacy of the bipolar RFA knife during per-oral endoscopic myotomy (POEM) and colonic ESD. The goal of our study is to prospectively evaluate the efficacy, safety and feasibility of Esophageal ESD using a novel Bipolar-Current ESD device.",[104,105,26,106],"Esophageal Neoplasm","Esophageal Polyp","Bipolar Electrocautery","2026-03-23",{"date":109,"type":32},"2026-03-25",{"date":111,"type":32},"2024-10-15",{"date":113,"type":21},"2027-12-31",{"name":115,"class":69},"Baylor College of Medicine",{"id":117,"slug":118,"hasResults":11,"nctId":119,"briefTitle":120,"officialTitle":121,"acronym":4,"eligibilityCriteria":122,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":123,"enrollmentInfo":124,"targetDuration":4,"studyType":50,"phases":126,"briefSummary":127,"conditions":128,"keywords":130,"overallStatus":133,"whyStopped":4,"lastUpdateSubmitDate":134,"lastUpdatePostDateStruct":135,"startDateStruct":137,"completionDateStruct":139,"leadSponsor":140,"locationsCount":4},"100631012","the-improvement-effect-of-real-time-artificial-intelligence-assisted-identification-of-bleeding-points-on-hemostasis-efficiency-in-endoscopic-submucosal-dissection-100631012","NCT07495137","The Improvement Effect of Real-time Artificial Intelligence Assisted Identification of Bleeding Points on Hemostasis Efficiency in Endoscopic Submucosal Dissection","The Improvement Effect of Real-time Artificial Intelligence Assisted Identification of Bleeding Points on Hemostasis Efficiency in Endoscopic Submucosal Dissection (ESD): a Multicenter, Randomized Controlled Trial","Inclusion Criteria\n\n1. Aged 18-80 years;\n2. Lesions meet the indications for ESD treatment of the esophagus, stomach, or colorectum according to relevant guidelines;\n3. Anticoagulant drugs have been suspended according to relevant guidelines;\n4. Patients with American Society of Anesthesiologists (ASA) classification Grade I or II;\n5. Patients who voluntarily sign the informed consent form.\n\nExclusion Criteria\n\n1. Patients with severe cardiopulmonary diseases, coagulation dysfunction or other severe comorbidities that may increase surgical risks;\n2. Patients undergoing dialysis treatment;\n3. Pregnant or lactating women;\n4. Deemed unsuitable for participation in this study by the principal investigator or other researchers.","80 Years",{"count":125,"type":21},160,[52],"The goal of this clinical trial is to learn if an artificial intelligence (AI) system that identifies bleeding points in real time can help stop bleeding faster during endoscopic submucosal dissection (ESD) - a minimally invasive surgery for early digestive tract cancer or precancerous lesions. It will also learn about the AI system's effect on surgery-related problems (like perforation or delayed bleeding) and total surgery time.\n\nThe main questions it aims to answer are:\n\n1. Does the AI system shorten the time it takes to stop each bleed during ESD?\n2. How does the AI system affect the rate of surgery-related problems and total surgery time?\n\nResearchers will compare two groups to see if the AI system improves hemostasis efficiency:\n\n1. AI group: During ESD, the AI system will real-time spot and mark bleeding points. Doctors will use these marks to stop bleeding.\n2. Control group: Doctors will use the same equipment but without the AI system - they will find and stop bleeding using their own experience.\n\nParticipants will:\n\n1. Have ESD surgery for esophageal, stomach, or colorectal lesions that need this treatment;\n2. Be randomly assigned to either the AI group or the control group;\n3. Attend follow-up checks in 14 days after surgery to check for complications;\n4. Have their surgery videos reviewed by experts to record hemostasis time and total surgery time.",[26,129],"Endoscopic Submucosal Dissection (ESD)",[131,132],"Endoscopic submucosal dissection","Artificial intelligence","NOT_YET_RECRUITING","2026-03-22",{"date":136,"type":32},"2026-03-27",{"date":138,"type":21},"2026-03-31",{"date":113,"type":21},{"name":141,"class":69},"Qilu Hospital of Shandong University",{"id":143,"slug":144,"hasResults":11,"nctId":145,"briefTitle":146,"officialTitle":146,"acronym":4,"eligibilityCriteria":147,"healthyVolunteers":148,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":149,"targetDuration":4,"studyType":50,"phases":150,"briefSummary":151,"conditions":152,"keywords":156,"overallStatus":133,"whyStopped":4,"lastUpdateSubmitDate":158,"lastUpdatePostDateStruct":159,"startDateStruct":161,"completionDateStruct":163,"leadSponsor":165,"locationsCount":4},"100616457","comparison-of-the-effects-of-target-controlled-infusion-method-and-manual-propofol-administration-on-respiratory-function-recovery-and-electroencephalogram-in-endoscopic-submucosal-dissection-cases-100616457","NCT07305857","Comparison of the Effects of Target-Controlled Infusion Method and Manual Propofol Administration on Respiratory Function, Recovery, and Electroencephalogram in Endoscopic Submucosal Dissection Cases","Inclusion Criteria:\n\n* Age: 18-75 years old\n* ASA (American Society of Anaesthesiologists) physical status class I-III\n* Patients with indications for ESD\n* BMI \\\u003C 35 kg\u002Fm²\n* Patients who are cooperative and can be monitored\n\nExclusion Criteria:\n\n* Those with cardiac or pulmonary insufficiency,\n* Those with neurological diseases,\n* Those with severe hepatic or renal dysfunction,\n* Those with psychiatric disorders that could affect their level of consciousness,\n* Those with allergies or hypersensitivity to propofol, midazolam, and fentanyl, Patients who refuse to participate in the study will not be included in this clinical trial.",true,{"count":101,"type":21},[52],"Endoscopic submucosal dissection (ESD) has become widely used as a minimally invasive alternative for the resection of early-stage gastrointestinal neoplasms. Due to the lengthy procedure time and intense pain caused by stretching, cutting, and dissecting the gastric wall during ESD, a deeper level of sedation is recommended compared to traditional endoscopic procedures (1). While ensuring adequate patient immobilisation during ESD, preserving respiratory function and rapid recovery are important clinical goals.\n\nTotal intravenous anaesthesia (TIVA) is an alternative method to inhalation anaesthesia, achieved through the combination of agents such as propofol and remifentanil. TIVA applications can be performed using manual or target-controlled infusion (TCI) systems. TCI systems aim to achieve and maintain the targeted plasma or effect site concentration based on pharmacokinetic models. These systems have been shown to provide advantages such as more stable depth of sedation during endoscopy, less haemodynamic fluctuation, and faster recovery (2-4).\n\nPreserving spontaneous breathing is preferred during ESD procedures, which requires careful monitoring of respiration. The Capnostream® device records four variables (SpO₂, RR, non-invasive EtCO₂, heart rate) every 30 seconds via a nasal cannula and integrates them into a single, dimensionless value called the integrated pulmonary index (IPI). The IPI can range from 1 to 10, with 4 and below requiring intervention and 8 to 10 representing the normal range. Furthermore, the use of the bispectral index (BIS) enables objective monitoring of anaesthesia depth by analysing EEG waves and can increase the safety of the recovery process (5).\n\nThis study aims to compare the effects of manual TIVA and TCI applications on recovery time, BIS, and respiratory parameters during ESD procedures in the stomach or colon region performed under sedation in the endoscopy unit. The findings will contribute to the safer and more effective planning of sedation applications.\n\nReferences;\n\n1. Sasaki T, Tanabe S, Azuma M, Sato A, Naruke A, Ishido K, et al. Propofol sedation with bispectral index monitoring is useful for endoscopic submucosal dissection: a randomised prospective phase II clinical trial. Endoscopy. 2012 Jun;44(6):584-9.\n2. Chang YT, Tsai TC, Hsu H, Chen YM, Chi KP, Peng SY. Sedation for gastrointestinal endoscopy with the application of target-controlled infusion. Turk J Gastroenterol Off J Turk Soc Gastroenterol. 2015 Sep;26(5):417-22.\n3. Sarraj R, Theiler L, Vakilzadeh N, Krupka N, Wiest R. Propofol sedation in routine endoscopy: A case series comparing target controlled infusion vs manually controlled bolus concept. World J Gastrointest Endosc. 2024 Jan 16;16(1):11-7.\n4. García Guzzo ME, Fernandez MS, Sanchez Novas D, Salgado SS, Terrasa SA, Domenech G, et al. Deep sedation using propofol target-controlled infusion for gastrointestinal endoscopic procedures: a retrospective cohort study. BMC Anaesthesiol. 10 August 2020;20(1):195.\n5. Sandler NA, Hodges J, Sabino M. Assessment of recovery in patients undergoing intravenous conscious sedation using bispectral analysis. J Oral Maxillofac Surg Off J Am Assoc Oral Maxillofac Surg. 2001 Jun;59(6):603-11; discussion 611-612.\n6. Ding Y, White PF. Simplified quality of anaesthesia scoring system. Anaesthesia. 1992 Oct;47(10):906-7.",[26,153,154,155],"Target Controlled Infusion of Propofol","Endoscopy Unit","Respiratory Complications",[58,157],"target controlled infusion of propofol","2025-12-12",{"date":160,"type":32},"2025-12-26",{"date":162,"type":21},"2026-01-01",{"date":164,"type":21},"2027-03-01",{"name":166,"class":69},"Marmara University Pendik Training and Research Hospital",{"id":168,"slug":169,"hasResults":11,"nctId":170,"briefTitle":171,"officialTitle":172,"acronym":4,"eligibilityCriteria":173,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":78,"enrollmentInfo":174,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":176,"conditions":177,"keywords":183,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":189,"lastUpdatePostDateStruct":190,"startDateStruct":192,"completionDateStruct":194,"leadSponsor":196,"locationsCount":40},"100422394","endoscopic-resection-of-gastrointestinal-neoplasms-100422394","NCT04780256","Endoscopic Resection of Gastrointestinal Neoplasms","Retrospective Study of Efficacy and Safety of the Endoscopic Removal of Cancerous and Precancerous Lesions of the Upper and Lower Digestive Tract","Inclusion Criteria:\n\n* 18 years or older\n* all patients who have undergone endoscopic resection of an upper or lower digestive tract tumor\n\nExclusion Criteria:\n\n* age under 18\n* inability to provide informed consent",{"count":175,"type":21},2000,"The study aims to retrospectively investigate the endoscopic resection procedures of cancerous and precancerous lesions of the upper and lower digestive tract in order to evaluate the efficacy and safety outcomes and to compare different resection techniques. In particular, the resection techniques investigated will be mucosectomy, en bloc and piecemeal, endoscopic submucosal dissection (ESD) and its variants, full-thickness resection. The anatomical districts involved will be the esophagus, stomach, duodenum, colon and rectum.",[178,26,179,180,181,182],"Endoscopic Mucosal Resection","Gastric Neoplasm","Colonic Neoplasms","Esophageal Neoplasms","Duodenal Neoplasms",[184,185,186,187,188],"Endoscopic mucosal resection (EMR)","Endoscopic submucosal dissection (ESD)","Endoscopic full thickness resection (EFTR)","Colorectal ESD","Colorectal EMR","2025-09-30",{"date":191,"type":32},"2025-10-03",{"date":193,"type":32},"2021-03-15",{"date":195,"type":21},"2025-12",{"name":197,"class":39},"Azienda USL Reggio Emilia - IRCCS",{"id":199,"slug":200,"hasResults":11,"nctId":201,"briefTitle":202,"officialTitle":203,"acronym":4,"eligibilityCriteria":204,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":123,"enrollmentInfo":205,"targetDuration":4,"studyType":50,"phases":206,"briefSummary":207,"conditions":208,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":211,"lastUpdatePostDateStruct":212,"startDateStruct":214,"completionDateStruct":216,"leadSponsor":218,"locationsCount":40},"100573597","safety-and-efficacy-of-traction-robot-assisted-endoscopic-submucosal-dissection-for-early-gastric-cancer-100573597","NCT06748352","Safety and Efficacy of Traction Robot-assisted Endoscopic Submucosal Dissection for Early Gastric Cancer","Safety and Efficacy of Traction Robot-assisted Endoscopic Submucosal Dissection for Early Gastric Cancer: a Pilot Randomized Controlled Study","Inclusion Criteria:\n\n* Patients aged 18-80.\n* Patients with pathologically verified high-grade intraepithelial neoplasia (HGIN) or intramucosal carcinoma of the stomach.\n\nExclusion Criteria:\n\n* Patients have lesions with confirmed or potential deep submucosal invasion or lymph node metastasis.\n* Patients with severe underlying diseases precluding endotracheal intubation, general anesthesia, or surgery.\n* Patients have a history of gastric malignancy with previous radiotherapy or operative treatment leading to changes in gastric structure.\n* Patients have lesions with local recurrence after endoscopic resection.\n* Patients unable to obtain informed consent.",{"count":101,"type":21},[52],"The goal of this clinical trial is to investigate whether the flexible auxiliary single-arm transluminal endoscopic robot (FASTER) system can improve the safety of the endoscopic submucosal dissection (ESD). It will also evaluate the efficacy of the system, such as whether it could reduce the procedure time and so on. The main questions it aims to answer are:\n\nDoes the use of the FASTER system reduce the number of muscular injuries, improving the safety of the ESD procedure? Does the use of the FASTER system reduce the procedure and dissection time, improving the efficacy of the ESD procedure? Researchers will compare FASTER-assisted ESD and conventional ESD to evaluate the safety and efficacy of the FASTER system.\n\nParticipants will:\n\nBe randomly assigned to the group with ESD using the traditional procedure or to the group with ESD assisted by the FASTER system.\n\nKeep a diary of their symptoms after the procedure. ESD has gained widespread acceptance as the standard method for treating early-stage gastrointestinal cancers. Adequate exposure of the submucosa layer through effective tissue traction is vital for the safe and effective performance of ESD. The FASTER system is designed to overcome this technical difficulty.",[209,26,210],"Early Gastric Cancer","Robot Surgery","2024-12-21",{"date":213,"type":32},"2024-12-27",{"date":215,"type":21},"2024-12-30",{"date":217,"type":21},"2025-03-01",{"name":219,"class":69},"Shandong University",{"id":221,"slug":222,"hasResults":11,"nctId":223,"briefTitle":224,"officialTitle":225,"acronym":226,"eligibilityCriteria":227,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":228,"targetDuration":4,"studyType":50,"phases":230,"briefSummary":231,"conditions":232,"keywords":234,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":238,"lastUpdatePostDateStruct":239,"startDateStruct":241,"completionDateStruct":243,"leadSponsor":245,"locationsCount":92},"100563054","local-levobupivacaine-for-pain-relief-after-endoscopic-submucosal-dissection-for-esophageal-lesions-100563054","NCT06611176","Local LevoBupivacaine for Pain Relief After Endoscopic Submucosal Dissection for Esophageal Lesions","Local Levobupivacaine for Pain Relief After Endoscopic Submucosal Dissection for Esophageal Lesions: a Randomized Controlled Trial","BESD-RCT","Inclusion Criteria:\n\n* Patients age ≥18 years at time of consent\n* Visible lesion in the esophagus, minimum diameter of the lesion ≥20 mm\n* Scheduled for esophageal ESD\n* Informed consent\n\nExclusion Criteria:\n\n* Presence of multiple lesions requiring two or more separate endoscopic resections\n* History of esophageal surgery other than fundoplications\n* History of esophageal ablation therapy\n* History of radiotherapy of the esophagus\n* Esophageal varices\n* Prior endoscopic resection in the same area\n* Uncontrolled coagulopathy\n* Severe medical comorbidities precluding endoscopy\n* Allergy to LB or other amide-type local anaesthesia\n* Current regular use of opioids\n* Other aetiology causing pain similar to post-ESD pain\n* Inability to assess pain due to severe psychiatric or neurological disease\n* Insufficient command of Dutch language\n* Brugada syndrome\n* Incapacitated patients",{"count":229,"type":21},88,[52],"Endoscopic submucosal dissection (ESD) is commonly performed for (pre)cancerous lesions in the esophagus. Following ESD, post-procedural chest pain is seen in many patients. Studies have shown that local bupivacaine (BP) into the residual submucosal layer of the resection wound after gastric ESD could reduce post-procedural pain rates effectively. Levobupivacaine (LB) is equipotent to BP regarding analgesic effects, but has a better safety profile. No studies have been performed to evaluate the efficacy of LB after esophageal ESD to reduce pain. Therefore, we want to evaluate the effect on post-procedural pain of local application of LB during esophageal ESD.",[26,233],"Levobupivacaine",[58,235,236,237],"ESD","esophagus","analgesic","2024-11-27",{"date":240,"type":32},"2024-12-02",{"date":242,"type":32},"2024-10-24",{"date":244,"type":21},"2026-03-30",{"name":246,"class":69},"Laura Boer",{"id":248,"slug":249,"hasResults":11,"nctId":250,"briefTitle":251,"officialTitle":251,"acronym":4,"eligibilityCriteria":252,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":253,"enrollmentInfo":254,"targetDuration":4,"studyType":50,"phases":256,"briefSummary":257,"conditions":258,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":259,"lastUpdatePostDateStruct":260,"startDateStruct":262,"completionDateStruct":264,"leadSponsor":265,"locationsCount":40},"100464148","the-relationship-between-scar-formation-and-esd-depth-in-therapy-for-gastric-carcinoma-100464148","NCT05323929","The Relationship Between Scar Formation and ESD Depth in Therapy for Gastric Carcinoma","Inclusion Criteria:\n\n* Patients older than 18 years old and younger than 75 years old.\n* Early gastric cancer (T1a stage) diagnosed by gastroscopy or ultrasonography, differentiated and no ulcer; or early gastric cancer (T1a stage), differentiated with ulcer, lesion diameter \\\u003C3cm; or early gastric cancer (T1a stage), undifferentiated and No ulcer, lesion diameter \\\u003C2cm.\n* Pathological diagnosis of gastric cancer.\n* No further treatment is required.\n* Patients diagnosed for the first time without other serious gastrointestinal diseases.\n\nExclusion Criteria:\n\n* Those who did not comply with the test requirements, obviously violated this protocol, or switched to other protocols in the middle of treatment.\n* Advanced gastric cancer; or undifferentiated gastric cancer lesions \\> 2 cm in diameter; or differentiated gastric cancer with ulcer lesions \\> 3 cm in diameter.\n* Coagulation disorders.\n* Serious heart, liver, kidney and other diseases, can not tolerate ESD treatment.\n* Patients with gastric cancer complications such as gastrointestinal bleeding and perforation that need emergency treatment.\n* Patients with distant metastasis.\n* Patients with other tumors, patients with a history of malignant tumors (except early carcinoma in situ.\n* The patient himself requests to withdraw from the trial.\n* The researcher believes that the patient is not suitable to participate in this study.","75 Years",{"count":255,"type":21},200,[52],"This study is a single-center, prospective, group-controlled clinical trial, aiming to clarify the relationship between the depth of dissection and scar formation in the treatment of early gastric cancer by ESD, and to provide high-quality evidence-based medicine for the treatment of early gastric cancer.",[209,26],"2022-04-12",{"date":261,"type":32},"2022-04-14",{"date":263,"type":32},"2022-01-01",{"date":113,"type":21},{"name":266,"class":69},"Second Affiliated Hospital, School of Medicine, Zhejiang University"]